• Terence O'Reilly, Paul Michael John McSheehy, Fritz Wenger, Marc Hattenberger, Melanie Muller, Juliane Vaxelaire, Karl-Heinz Altmann, and Markus Wartmann.
• Novartis Institutes for BioMedical Research, Oncology Research, Basel, Switzerland.
• Prostate. 2005 Nov 1; 65 (3): 231-40.

BackgroundMicrotubule agents appear promising for the treatment of prostate cancer. Patupilone (epothilone B), a highly potent non-taxane microtubule stabilizing agent, was evaluated in models of androgen-independent prostate cancer.MethodsPatupilone was administered to athymic mice bearing human prostate cancer xenografts (subcutaneous DU 145 and PC-3M, orthotopic PC-3M).ResultsOne 4 mg/kg patupilone administration produced transient regression of DU 145 tumors, while two weekly administrations of 2.5 mg/kg produced stable disease followed by protracted regression, however with more pronounced body weight loss. Taxol (15 mg/kg every other day) weakly inhibited tumor growth, but with less body weight loss. Patupilone (5 mg/kg) produced protracted growth inhibition of subcutaneous PC-3M tumors, with transient body weight loss. In mice with orthotopic PC-3M tumors, 4 or 5 mg/kg/week patupilone impaired primary tumor growth, abrogated metastases and enhanced survival, with only transient body weight loss.ConclusionsThese data suggest that patupilone holds promise for prostate cancer treatment.Copyright 2005 Wiley-Liss, Inc

21 keywords...

hide…